Calrezdy (calcuim chloride)

Where it stands

According to the official record, the FDA approved Calrezdy on 2026-10-19. The product is listed as calcium chloride (spelled "calcuim chloride" in the source record), supplied as a solution. The sponsor is shown as "Fresenius Medcl Care", as written in the record. The application number is NDA219456.

The record does not give the therapeutic area or the approved indication. It therefore cannot support any statement about the patient population, dosing, route of administration or place in therapy. Anyone needing those details should read the FDA-approved labeling directly.

The only milestone on file is the approval itself. There is no earlier US milestone (submission, filing, advisory committee, or review-clock date), so the review timeline cannot be reconstructed from these records.

Regulatory pathway and designations

The application is an NDA, the standard US route for a new drug product, and the record's only designation is "New active ingredient". Nothing is recorded on expedited programs (priority review, fast track, breakthrough), orphan status, or any other special pathway. None should be assumed.

The "new active ingredient" label is worth verifying. Calcium chloride is a long-established compound, so the classification may reflect the specific product or application type rather than the molecule's novelty. The records do not explain the basis, and this analysis does not speculate. Check the FDA's approval documentation to confirm how the agency classified it and what that implies for exclusivity.

The CHMP opinion date is blank, which is expected for a US-only record. The records show no EU filing or EMA procedure for this product.

Safety and pharmacovigilance

The records contain no safety information. They list no boxed warning, contraindications, adverse-event data, REMS, or postmarketing requirements or commitments, so no safety profile can be described here.

As with any newly approved US product, routine pharmacovigilance applies: the sponsor's adverse-event reporting obligations and FDA's postmarketing surveillance. Any product-specific risk-management measures would be found in the approved labeling and approval letter, which are not part of these records.

What to watch

First, obtain the approved prescribing information and approval letter to confirm the indication, strength and presentation, any postmarketing requirements, and the exclusivity granted. These are the main gaps in the current record.

Second, watch for the commercial launch and any label updates after approval. The records give no information on launch timing, supply, or ex-US filings, so none of these can be assessed from the available data.